Is Ticagrelor registered with the SFDA?

The SFDA human drug list (edition 4-2026, as published by the Council of Health Insurance) lists 19 valid registrations of Ticagrelor, including BRILINTA 60 MG FILM COATED TABLET (60 mg, Film-coated tablet, SAR 153.50); BRILINTA 90 MG FILM COATED TABLET (90 mg, Film-coated tablet, SAR 195.60); Briglor (90 mg, Film-coated tablet, SAR 167.65); Briglor (60 mg, Film-coated tablet, SAR 142.50); Domassel (90 mg, Film-coated tablet, SAR 167.65).

Is Ticagrelor approved by the US FDA?

Drugs@FDA lists 22 application product lines for Ticagrelor, including BRILINTA (Prescription); TICAGRELOR (Prescription); TICAGRELOR (Prescription); TICAGRELOR (Prescription); TICAGRELOR (Prescription).

Is Ticagrelor authorised in the European Union?

EMA lists 1 centrally authorised medicine containing Ticagrelor: Brilique.

Are there safety signals or safety updates for Ticagrelor?

EMA PRAC: 3 entries; US FDA: 1 entry (latest 2026-05-07).

Active substance

Ticagrelor

SFDA 19
US FDA 22
EMA 2
Health Canada 12
US price lines 4
NHS prices 3
Safety 4

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade name	Strength	Form · route	Pack	Public price	Type	Company	Status
BRILINTA 60 MG FILM COATED TABLET	60 mg	Film-coated tablet · Oral use	56 Blister	SAR 153.50	NCE · Prescription	AstraZeneca AB	Valid
BRILINTA 90 MG FILM COATED TABLET	90 mg	Film-coated tablet · Oral use	56 Bottle	SAR 195.60	NCE · Prescription	AstraZeneca	Valid
Briglor	90 mg	Film-coated tablet · Oral use	60 Blister	SAR 167.65	Generic · Prescription	Saudi Amarox	Valid
Briglor	60 mg	Film-coated tablet · Oral use	60 Blister	SAR 142.50	Generic · Prescription	Saudi Amarox	Valid
Domassel	90 mg	Film-coated tablet · Oral use	60 Blister	SAR 167.65	Generic · Prescription	Pharma Pharmaceutical Industries (PPI)	Valid
Domassel	60 mg	Film-coated tablet · Oral use	60 Blister	SAR 131.55	Generic · Prescription	Pharma Pharmaceutical Industries (PPI)	Valid
Empani	90 mg	Film-coated tablet · Oral use	56 Blister	SAR 156.50	Generic · Prescription	Acino AG	Valid
Empani	60 mg	Film-coated tablet · Oral use	56 Blister	SAR 122.80	Generic · Prescription	Acino AG	Valid
Lotac	90 mg	Film-coated tablet · Oral use	60 Blister	SAR 151.80	Generic · Prescription	Alrai Pharmaceutical industry Co. (L.L.C)	Valid
Lotac	60 mg	Film-coated tablet · Oral use	60 Blister	SAR 153.50	Generic · Prescription	Alrai Pharmaceutical industry Co. (L.L.C)	Valid
Platica	90 mg	Film-coated tablet · Oral use	56 Blister	SAR 182.55	Generic · Prescription	SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO	Valid
Prasido	90 mg	Film-coated tablet · Oral use	56 Blister	SAR 156.50	Generic · Prescription	Med City Pharma	Valid
Survilor	90 mg	Film-coated tablet · Oral use	56 Blister	SAR 156.40	Generic · Prescription	Apex Pharma	Valid
Tagbro	90 mg	Film-coated tablet · Oral use	60 Blister	SAR 167.65	Generic · Prescription	MS Pharma Saudi (MSPS)	Valid
Ticagard	90 mg	Film-coated tablet · Oral use	30 Blister	SAR 83.80	Generic · Prescription	Razy Al Madina Pharmaceutical	Valid
Ticaglob	90 mg	Film-coated tablet · Oral use	30 Blister	SAR 77.15	Generic · Prescription	Global NAPI Pharmaceuticals (GNP)	Valid
Ticagrelor	90 mg	Film-coated tablet · Oral use	30 Blister	SAR 83.80	Generic · Prescription	AJA PHARMACEUTICAL INDUSTRIES	Valid
Ticagrelor SPC F.C. Tablets	90 mg	Film-coated tablet · Oral use	30 Blister	SAR 83.80	Generic · Prescription	SUDAIR PHARMA COMPANY	Valid
Torrenta	90 mg	Film-coated tablet · Oral use	60 Blister	SAR 167.60	Generic · Prescription	APOTEX	Valid

Indications — CHI Daman Drug Formulary

NON-ST WAVE ELEVATED MYOCARDIAL INFARCTION (NSTEMI); ST-WAVE ELEVATED MYOCARDIAL INFARCTION (STEMI)

US FDA United States — FDA approvals (Drugs@FDA)

Product	Strength	Form · route	Applicant	Status	First approved
BRILINTA	90MG; 60MG	tablet · oral	ASTRAZENECA	Prescription	20 Jul 2011
TICAGRELOR	60MG; 90MG	tablet · oral	WATSON LABS INC	Prescription	4 Sep 2018
TICAGRELOR	90MG	tablet · oral	HISUN PHARM HANGZHOU	Prescription	23 Jan 2019
TICAGRELOR	90MG; 60MG	tablet · oral	SUNSHINE	Prescription	6 Apr 2020
TICAGRELOR	90MG; 60MG	tablet · oral	MSN	Prescription	7 Apr 2020
TICAGRELOR	60MG; 90MG	tablet · oral	MYLAN	Prescription	9 Jul 2021
TICAGRELOR	90MG	tablet · oral	ALKEM LABS LTD	Prescription	21 Apr 2023
TICAGRELOR	90MG	tablet · oral	PRINSTON INC	Prescription	16 Aug 2024
TICAGRELOR	90MG; 60MG	tablet · oral	DR REDDYS	Prescription	29 Oct 2024
TICAGRELOR	90MG; 60MG	tablet · oral	APOTEX	Prescription	1 May 2025
TICAGRELOR	90MG; 60MG	tablet · oral	ALEMBIC	Prescription	2 May 2025
TICAGRELOR	90MG; 60MG	tablet · oral	INVAGEN PHARMS	Prescription	5 May 2025
TICAGRELOR	60MG	tablet · oral	ALKEM LABS LTD	Prescription	28 Oct 2025
TICAGRELOR	60MG; 90MG	tablet · oral	TARO	Prescription	28 Oct 2025
TICAGRELOR	60MG; 90MG	tablet · oral	MACLEODS PHARMS	Prescription	28 Oct 2025
TICAGRELOR	60MG; 90MG	tablet · oral	CHANGZHOU PHARM	Prescription	28 Oct 2025
TICAGRELOR	60MG; 90MG	tablet · oral	SCIEGEN PHARMS	Prescription	28 Oct 2025
TICAGRELOR	60MG; 90MG	tablet · oral	MANKIND PHARMA	Prescription	6 Feb 2026
TICAGRELOR	60MG; 90MG	tablet · oral	ZHEJIANG JINGXIN	Prescription	24 Mar 2026
TICAGRELOR	60MG; 90MG	tablet · oral	MICRO LABS	Prescription	27 Apr 2026
TICAGRELOR	60MG; 90MG	tablet · oral	PHARMOBEDIENT	Prescription	20 Aug 2026
TICAGRELOR	90MG; 60MG	tablet · oral	AMNEAL	Discontinued	23 Jan 2019

EMA European Union — centrally authorised medicines

Brilique AstraZeneca AB · Authorised · authorised 3 Dec 2010 · ATC B01AC24

Therapeutic indication (EMA)

Brilique, co administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (ACS) or a history of myocardial infarction (MI) and a high risk of developing an atherothrombotic event Brilique, co-administered with acetyl salicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with a history of myocardial infarction (MI occurred at least one year ago) and a high risk of developing an atherothrombotic event.

Possia AstraZeneca AB · Withdrawn · authorised 3 Dec 2010 · ATC B01AC24

Therapeutic indication (EMA)

Possia, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (unstable angina, non-ST-elevation myocardial infarction [NSTEMI] or ST-elevation myocardial infarction [STEMI]); including patients managed medically, and those who are managed with percutaneous coronary intervention (PCI) or coronary artery by-pass grafting (CABG).

Canada Canada — marketed products (Health Canada)

Brand	DIN	Strength	Form · route	Company
AG-TICAGRELOR	02537184	60 MG	TABLET · ORAL	ANGITA PHARMA INC.
AG-TICAGRELOR	02537192	90 MG	TABLET · ORAL	ANGITA PHARMA INC.
APO-TICAGRELOR	02482622	60 MG	TABLET · ORAL	APOTEX INC
APO-TICAGRELOR	02482630	90 MG	TABLET · ORAL	APOTEX INC
BRILINTA	02368544	90 MG	TABLET · ORAL	ASTRAZENECA CANADA INC
BRILINTA	02455005	60 MG	TABLET · ORAL	ASTRAZENECA CANADA INC
JAMP TICAGRELOR	02531798	60 MG	TABLET · ORAL	JAMP PHARMA CORPORATION
JAMP TICAGRELOR	02531801	90 MG	TABLET · ORAL	JAMP PHARMA CORPORATION
M-TICAGRELOR	02529750	60 MG	TABLET · ORAL	MANTRA PHARMA INC
M-TICAGRELOR	02529769	90 MG	TABLET · ORAL	MANTRA PHARMA INC
TARO-TICAGRELOR	02492571	60 MG	TABLET · ORAL	TARO PHARMACEUTICALS INC
TARO-TICAGRELOR	02492598	90 MG	TABLET · ORAL	TARO PHARMACEUTICALS INC

Prices — United States and England

Source	Product as listed	Price	Unit / pack	Date
US NADAC	BRILINTA 60 MG TABLET	$7.41915	per EA	23 Sep 2026
US NADAC	BRILINTA 90 MG TABLET	$7.42045	per EA	23 Sep 2026
US NADAC	TICAGRELOR 60 MG TABLET	$0.28214	per EA	23 Sep 2026
US NADAC	TICAGRELOR 90 MG TABLET	$0.25291	per EA	23 Sep 2026
NHS Drug Tariff	Ticagrelor 60mg tablets	£2.27	56 tablet	1 Oct 2026
NHS Drug Tariff	Ticagrelor 90mg orodispersible tablets sugar free	£54.60	56 tablet	1 Oct 2026
NHS Drug Tariff	Ticagrelor 90mg tablets	£2.50	56 tablet	1 Oct 2026

NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.

Safety signals and safety-related labeling changes

US FDA 7 May 2026 BRILINTA — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
EMA PRAC 5 Sep 2019 PRAC signal: Severe cutaneous adverse reactions (SCARs)
Action for MAH: update of the product information: No
EMA PRAC 11 Apr 2019 PRAC signal: Severe cutaneous adverse reactions (SCARs)
Action for MAH: update of the product information: No
EMA PRAC 7 Feb 2013 PRAC signal: Food interaction with grapefruit juice
Action for MAH: update of the product information: Yes

All safety entries for ticagrelor →

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.